Literature DB >> 21115923

Myxoid liposarcoma with EWS-CHOP type 1 fusion gene.

Kayo Suzuki1, Yoshito Matsui, Kenji Endo, Takahiro Kubo, Tadashi Hasegawa, Tomoatsu Kimura, Osamu Ohtani, Natsuo Yasui.   

Abstract

BACKGROUND: In myxoid liposarcoma (MLS), the t(12;16)(q13;p11) chromosomal translocation and its resultant fusion transcript, the human translocation liposarcoma (TLS)-CCAAT/enhancer binding protein (C/EBP) homologous protein (CHOP), are found in the majority of cases. On the other hand, the variant translocation, t(12;22)(q13;q12) creating the Ewing sarcoma (EWS)-CHOP fusion transcript, is detectable in a limited number of cases. PATIENTS AND METHODS: Tissue from MLS arising in the left thigh of a 19-year-old female was analyzed for possible detection of chromosome translocation and fusion transcript. Fluorescent in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR) methods were used.
RESULTS: FISH analysis demonstrated a rearrangement in the CHOP gene. RT-PCR analysis confirmed the presence of EWS-CHOP chimeric transcript type 1, in which exon 7 of EWS was in-frame fused to exon 2 of CHOP with a serine (AGT) to methionine (ATG) transition at the junction. The patient underwent a radical segmental resection including a left vastus medialis musclectomy. Sixty months following the surgical resection, the patient was alive with no evidence of disease.
CONCLUSION: Analysis of MLS with EWS-CHOP variant transcripts, type 1 through type 4, including this case together with 15 cases in the literature, indicated that MLS with type 1 fusion transcript may show a more favorable clinical behavior than MLS with other types of fusion transcript.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115923

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Variation in myxoid liposarcoma: Clinicopathological examination of four cases with detectable TLS-CHOP or EWS-CHOP fusion transcripts whose histopathological diagnosis was other than myxoid liposarcoma.

Authors:  Kayo Suzuki; Yoshito Matsui; Nobuyuki Hashimoto; Norifumi Naka; Nobuhito Araki; Tomoatsu Kimura; Hideki Yoshikawa; Takafumi Ueda
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

Review 2.  Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.

Authors:  Sarah Abaricia; Angela C Hirbe
Journal:  Curr Treat Options Oncol       Date:  2018-10-25

Review 3.  Molecular strategies for detecting chromosomal translocations in soft tissue tumors (review).

Authors:  Margherita Cerrone; Monica Cantile; Francesca Collina; Laura Marra; Giuseppina Liguori; Renato Franco; Annarosaria De Chiara; Gerardo Botti
Journal:  Int J Mol Med       Date:  2014-04-04       Impact factor: 4.101

Review 4.  Advances in the targeted therapy of liposarcoma.

Authors:  Zhonghai Guan; Xiongfei Yu; Haohao Wang; Haiyong Wang; Jing Zhang; Guangliang Li; Jiang Cao; Lisong Teng
Journal:  Onco Targets Ther       Date:  2015-01-05       Impact factor: 4.147

Review 5.  Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.

Authors:  Alessandro De Vita; Laura Mercatali; Federica Recine; Federica Pieri; Nada Riva; Alberto Bongiovanni; Chiara Liverani; Chiara Spadazzi; Giacomo Miserocchi; Dino Amadori; Toni Ibrahim
Journal:  Onco Targets Ther       Date:  2016-10-11       Impact factor: 4.147

Review 6.  Molecular detection and targeting of EWSR1 fusion transcripts in soft tissue tumors.

Authors:  Monica Cantile; Laura Marra; Renato Franco; Paolo Ascierto; Giuseppina Liguori; Annarosaria De Chiara; Gerardo Botti
Journal:  Med Oncol       Date:  2013-01-18       Impact factor: 3.064

7.  Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.

Authors:  Kayo Suzuki; Yoshito Matsui; Mami Higashimoto; Yoshiharu Kawaguchi; Shoji Seki; Hiraku Motomura; Takeshi Hori; Yasuhito Yahara; Masahiko Kanamori; Tomoatsu Kimura
Journal:  PLoS One       Date:  2012-05-03       Impact factor: 3.240

8.  Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masatoshi Naito
Journal:  Genet Res Int       Date:  2011-07-28

9.  The oncogenic transcription factor FUS-CHOP can undergo nuclear liquid-liquid phase separation.

Authors:  Izzy Owen; Debra Yee; Hala Wyne; Theodora Myrto Perdikari; Victoria Johnson; Jeremy Smyth; Robert Kortum; Nicolas L Fawzi; Frank Shewmaker
Journal:  J Cell Sci       Date:  2021-09-03       Impact factor: 5.235

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.